Key facts
- BluMaiden Biosciences’s last known valuation is $11.2M (Aug 2025).
- It has raised $4.4M; the latest was Later Stage VC in Jul 2024.
- Notable investors include SEEDS Capital, Amatar Investment, Angsana Investments, BONNECHANCE INVESTMENTS PTE. LTD., DG Holding — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for BluMaiden Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for BluMaiden Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BluMaiden Biosciences
Operator of a biotechnology firm intended to offer pharma services with clinical trial analytics powered by their proprietary artificial intelligence (AI)-driven technology. The company identifies licensable small-molecule drugs and biomarkers, guided by an industry-experienced leadership team, aiming to bring meaningful advancements that positively impact patients, enabling users to achieve direct clinical utility, such as drug response prediction, patient stratification, drug evaluation, and trial design.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2020
- Employees
- 11
- Website
- blumaiden.com/
- Ownership
- Privately Held (backing)
BluMaiden Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BluMaiden Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BluMaiden Biosciences in its N-PORT filings yet. We sweep new filings monthly.